Satraplatin: leading the new generation of oral platinum agents.

Abstract

BACKGROUND:

In recent years, JM-216/satraplatin (GPC Biotech, Inc.) has emerged as a novel oral platinum analogue with a better toxicity profile than cisplatin. Since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it appears to demonstrate efficacy in cisplatin-resistant cell lines. The preclinical and clinical evaluation of satraplatin stimulated this review of the pharmacology and clinical trial data of this agent.

METHODS:

A literature review was conducted in the MEDLINE database from 1985 to present using the keywords 'satraplatin' or 'JM-216'. The abstracts regarding satraplatin reported at the 2007 - 2009 American Society of Clinical Oncology meetings were also reviewed.

RESULTS/CONCLUSION:

Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA-approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate-resistant prostate cancer (CRPC), revealing an improvement in progression-free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel-refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.

• Authors: Ashish Bhargava, Ulka N Vaishampayan
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 18 Issue 11 Pg. 1787-97 (Nov 2009) ISSN: 1744-7658 [Electronic] England
• PMID: 19888874 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• satraplatin

Topics

• Administration, Oral
• Animals
• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Drug Resistance, Neoplasm
• Humans
• Neoplasms (drug therapy, physiopathology)
• Organoplatinum Compounds (adverse effects, pharmacology, therapeutic use)